In this study, we evaluated the sensitivity and performance of HCV drug resistance assay for detection of DCV-resistant mutations using direct sequencing and cycleave PCR. Direct sequencing analysis revealed that SVR rates were 93.5% (43/46) for the patients with Y93 wild, and 40.0% (6/15) for the patients with Y93H mutant. Furthermore, cycleave PCR analysis revealed that SVR rates were 97.4% (37/38) for the patients with Y93 wild, and 45.0% (9/20) for the patients with Y93H mutant. The SVR rate in patients with Y93 wild was higher in the combination method of direct sequencing and cycleave PCR (97.6%) than in the cycleave PCR alone. These results suggested that this assay may be useful indicator for treatment with DCV/ASV dual therapy.
